World

Why Guinea-Bissau halted a controversial hepatitis vaccine trial for babies

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 05/11/2026, 15:26:24 UTC.

Briefings

A Guinea-Bissau trial for hepatitis B vaccine was halted due to concerns that US funding would deny critical immunization to thousands of infants. The trial was originally scheduled for 2026, and the decision was made by local health authorities citing ethical risks. No specific numbers of infants affected are provided in the source, only the general scale of the potential impact.

Key points

• A Guinea-Bissau trial for hepatitis B vaccine was halted due to concerns that US funding would deny critical immunization to thousands of infants.
• The trial was originally scheduled for 2026, and the decision was made by local health authorities citing ethical risks.

Context

This finding highlights a potential conflict between international funding priorities and local public health needs in West Africa, where vaccine access remains a critical challenge.

Limitations

The source evidence is extremely sparse, providing no specific numbers of infants affected, dates of the decision beyond the trial's original 2026 schedule, or details on the specific ethical concerns raised by local authorities.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 06/11/2026, 13:17:18 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiduxnacktz5dujtno52qdylbtwmvvzrlnl36npw4jvfvzpdoijk4a